With ear­ly-stage stud­ies un­der­way, Con­nect Bio­phar­ma­ceu­ti­cals clos­es $55M round to ad­vance im­mune mod­u­la­tors

Hav­ing se­lect­ed a sec­ond im­mune mod­u­la­tor to move in­to the clin­ic eight months ago, Con­nect Bio­phar­ma­ceu­ti­cals now has $55 mil­lion to help fund its de­vel­op­ment.

The Suzhou-based biotech wel­comed Ad­van­tech Cap­i­tal as the lead in­vestor in the Se­ries B, which al­so fea­tured fa­mil­iar faces at Qim­ing Ven­ture Part­ners, North­ern Light Ven­ture Cap­i­tal, and Cowin Ven­ture.

The mon­ey will go to­ward a mul­ti­ple as­cend­ing dose tri­al of CBP-201, a IL-4Rα an­ti­body, in pa­tients with atopic der­mati­tis. As with lead drug CBP-307, Con­nect start­ed hu­man stud­ies in Aus­tralia, with Chi­na ap­pli­ca­tions like­ly to fol­low.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER